Garlic ingredient wipes out hospital superbugs in tests

John von Radowitz
Sunday 28 December 2003 20:00 EST
Comments

Your support helps us to tell the story

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.

At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.

The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.

Your support makes all the difference.

BAn ingredient in garlic may offer one of the best defences against hospital superbugs, research shows. The compound is said to be effective even against highly resistant strains of the notorious MRSA bug, which has claimed many lives.

Tests by Dr Ron Cutler, a microbiologist, showed it can cure patients with MRSA-infected wounds "within days", he said. Allicin, which occurs naturally in garlic, not only killed known varieties of MRSA, but also new superbug generations resistant to "last-resort" antibiotics such as vancomycin. The findings will be published in the Journal of Biomedical Science in the new year.

Dr Cutler, from the University of East London, said: "Antibiotics are increasingly ineffective [against MRSA]. Plant compounds have evolved over millions of years as chemical defence agents against infection. Garlic has been used in medicine for centuries."

MRSA (methicillin-resistant Staphylococcus aureus) causes 2,000 deaths in UK hospitals each year, mainly by infecting surgical wounds. Dr Cutler is starting clinical trials.

Join our commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies

Comments

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in